Healthcare
Live Price
Offline$8.95
+0.00% today
1Y Change
-30.89%
Window
Jun 23, 2025 → Jun 17, 2026
Coverage: 254 bars · Jun 23, 2025 → Jun 17, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Terveystalo Oyj (TTALF) is a Healthcare stock with a market cap of $990.00M and listed on OTC. The stock last traded around $8.95 and down 30.9% across the available one-year price window (Jun 23, 2025 → Jun 17, 2026). Baseline metrics include revenue growth of -4.6%, EPS growth of +28.1%, a dividend yield of 7.2%. What stands out right now is revenue -4.6%, EPS +28.1%, free cash flow -15.1% with operating margin 9.3% and ROIC 7.9%. The dividend matters to the case here, with a current yield around 7.2%. Valuation is more restrained than many high-expectation growth names at P/E 13.0 and price/sales 0.8. Overall, the current profile looks closer to a income-oriented value setup than a generic broad-market placeholder. Stock Foundry combines TTALF price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
TTALF
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
TTALF Max Drawdown
-30.89%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for TTALF and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$1.2B
-8.3% YoY
FY Net Income
$80.5M
+229.9% YoY
Free Cash Flow
$152.1M
+86.2% YoY
Revenue Growth
-4.6%
EPS Growth
+28.1%
Gross Margin
30.5%
Net Margin
6.2%
Income statement
EUR
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 1.3B | 1.3B | 1.3B | 1.3B | 1.2B |
| Gross Profit | 270M | 790M | 303M | 733M | 666M |
| Operating Income | 138M | 116M | -15M | 34M | 110M |
| EBITDA | 233M | 217M | 91M | 176M | 202M |
| Net Income | 93M | 72M | -42M | 24M | 81M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
EUR
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | 75M | 65M | 38M | 40M | 38M |
| Total Assets | 1.4B | 1.4B | 1.4B | 1.5B | 1.4B |
| Total Liabilities | 857M | 850M | 904M | 887M | 840M |
| Shareholder Equity | 584M | 548M | 515M | 592M | 609M |
| Total Debt | 735M | 570M | 636M | 607M | 557M |
| Net Debt | 660M | 505M | 598M | 567M | 519M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
195M
+38.5% YoY
Capital Expenditures
43M
+27.2% YoY
Free Cash Flow
152M
+86.2% YoY
Key ratios
Gross Margin
30.5%
Operating Margin
9.3%
Net Margin
6.2%
ROE
13.8%
Debt / Equity
1.17x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.